41

Ferritin tarkibida quruq massasiga nisbata 23 foizgacha temir (Fe) ionini saqlovchi oqsil sifatida Fransuz olimi Laufberger tomonidan Otning taloq to’qimasi tarkibidan ajratrib olibgan oqsil sifatida qayt etilgan.Ferritin oqsili hozirda keng qamrovli diagnostik vosita sifatida tibbiyotning barcha yo’nalishlari bo’ylab qo’llanib kelmoqda.Ushbu oqsilning birinchi bo’lib kashf etilgan inson organizmidagi funksiyasi bu temir ioni uchun depo sifatida qayt etilgan bo’lsa hozirda gemostaz tizimi, yallig’lanish jarayonlarida, onkologiyada hamda amaliy tibbiyotda sezilarli ahamiyatga ega bo‘lgan diagnostik vosita sifatida ishlatilinib kelinmoqda.Ushbu maqolada ferritin oqsilining ishlash mexanizmlari va klinik ahamiyatlari haqida tahliliy ma’lumotlar keltirilgan

  • Количество прочтений 41
  • Дата публикации 05-04-2025
  • Язык статьиO'zbek
  • Страницы15-22
Ўзбек

Ferritin tarkibida quruq massasiga nisbata 23 foizgacha temir (Fe) ionini saqlovchi oqsil sifatida Fransuz olimi Laufberger tomonidan Otning taloq to’qimasi tarkibidan ajratrib olibgan oqsil sifatida qayt etilgan.Ferritin oqsili hozirda keng qamrovli diagnostik vosita sifatida tibbiyotning barcha yo’nalishlari bo’ylab qo’llanib kelmoqda.Ushbu oqsilning birinchi bo’lib kashf etilgan inson organizmidagi funksiyasi bu temir ioni uchun depo sifatida qayt etilgan bo’lsa hozirda gemostaz tizimi, yallig’lanish jarayonlarida, onkologiyada hamda amaliy tibbiyotda sezilarli ahamiyatga ega bo‘lgan diagnostik vosita sifatida ishlatilinib kelinmoqda.Ushbu maqolada ferritin oqsilining ishlash mexanizmlari va klinik ahamiyatlari haqida tahliliy ma’lumotlar keltirilgan

№ Имя автора Должность Наименование организации
1 Xolmatov S.I. ! “Central Asian Medical University” xalqaro tibbiyot universiteti.
№ Название ссылки
1 1.Laufberger V. Sur la cristallisation de la ferritine. Bulletin de la Societe de chimie biologique 1937;19:1575–1582.2.Worwood, M. Iron in Biochemistry and Medicine, II. A.a.W. Jacobs, M., editor. London: Academic Press; 1980. p. 204-244.3.Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol 1972;25:326–329. [PubMed: 5063755]4.Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J 1972;4:206–208. [PubMed: 5082548]5.Jacobs A, Worwood M. Ferritin in serum. Clinical and biochemical implications. N Engl J Med1975;292:951–956. [PubMed: 1090831]6.Li JY, Paragas N, Ned RM, Qiu A, Viltard M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, Williams D, Lin CS, Schmidt-Ott KM, Andrews NC, Barasch J. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell 2009;16:35–46. [PubMed: 19154717]7.Sibille JC, Kondo H, Aisen P. Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein. Hepatology 1988;8:296–301. [PubMed: 3356411] 8.Leimberg MJ, Prus E, Konijn AM, Fibach E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. J Cell Biochem 2008;103:1211–1218. [PubMed:17902167]9.Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999;21:396–399. [PubMed: 10192390]10.Schier WW, Roth A, Ostroff G, Schrift MH. Hodgkin's disease and immunity. Am J Med 1956;20:94–99. [PubMed: 13282926]11.Izak G, Stupp Y, Manny N, Zajicek G, Weiss DW. The immune response in acutemyelocytic leukemia: effect of the methanol extraction residue fraction of tubercle bacilli (MER) on T and B cell functions and their relation to the course of the disease. Isr J Med Sci 1977;13:677–693. [PubMed:411767]12.Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature 1977;265:755–756. [PubMed: 67563]13.Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol 1979;42:345–353. [PubMed: 157770]14.Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006;1 Suppl 1:S9–S18.[PubMed: 17699375]15.Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007;6:457–463. [PubMed: 17643933]16.Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009;46:387–393. [PubMed: 19786207]17.Weinberg ED, Miklossy J. Iron withholding: a defense against disease. J Alzheimers Dis 2008;13:451–463. [PubMed: 18487852]18.Torti SV, Torti FM. Human H-kininogen is a ferritin-binding protein. J Biol Chem 1998;273:13630–13635. [PubMed: 9593701]19.Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system:from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007;98:77–83. [PubMed: 17597995]20.Sharma JN. The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection. Inflammopharmacology 2005;12:591–596. [PubMed: 16259723]21.Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des2006;12:2599–2607. [PubMed: 16842160]22.Guo YL, Colman RW. Two faces of high-molecular-weight kininogen (HK) in angiogenesis:bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost 2005;3:670–676.[PubMed: 15733059]23.Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643–651.[PubMed: 14601638]24.Parthasarathy N, Torti SV, Torti FM. Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J 2002;365:279–286. [PubMed: 12071855]25.Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D'Agostino RB Jr, Lively MO, Hua X, Tilley SL, Muller-Esterl W, Willingham MC, Torti FM, Torti SV. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol26.2008;294:L505–L515. [PubMed: 18192590]27.Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 2009;106:570–575. [PubMed: 19126685]28.Kirkali Z, Guzelsoy M, Mungan MU, Kirkali G, Yorukoglu K. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume. Urol Int 1999;62:21–25. [PubMed:10436426]29.Cazzola M, Arosio P, Bellotti V, Bergamaschi G, Dezza L, Iacobello C, Ruggeri G, Zappone E, Albertini A, Ascari E. Immunological reactivity of serum ferritin in patients with malignancy. Tumori 1985;71:547–554. [PubMed: 4082287]30.Lukina EA, Levina AA, Mokeeva RA, Tokarev Yu N. The diagnostic significance of serum ferritin indices in patients with malignant and reactive histiocytosis. Br J Haematol 1993;83:326–329. [PubMed: 8457481]31.Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 1998;58:473–478. [PubMed: 9458092]32.Marcus DM, Zinberg N. Measurement of serum ferritin by radioimmunoassay: results in normal individuals andpatients with breast cancer. J Natl Cancer Inst 1975;55:791–795. [PubMed: 1185803]33.Elliott RL, Elliott MC, Wang F, Head JF. Head, Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann N Y Acad Sci1993;698:159–166. [PubMed: 8279755]34.Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast Cancer 1982;50:2406–2409. [PubMed: 7139533]35.Rossiello R, Carriero MV, Giordano GG. Distribution of ferritin, transferrin andlactoferrin in breast carcinoma tissue. J Clin Pathol 1984;37:51–55. [PubMed: 6323544]36.Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, Halliday JW, Bassett ML,Powell LW. Cohort study of internal malignancy in genetic hemochromatosis and other chronicnonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81–84. [PubMed: 2989605]37.Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N.Engl.J.Med 1985;313:1256–1262. [PubMed: 4058506]38.Холматов Ш.И. ИНТЕРЛЕЙКИНЛАРНИНГ МИОКАРД ИНФАРКТИ АСОРАТЛАРИНИ КАМАЙТИРИШДАГИ РОЛИ. Actacamu, 6(6), 15–18. https://doi.org/10.5281/zenodo.1280367139.Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007;18:1047–1053. [PubMed: 17823849]
В ожидании